194 related articles for article (PubMed ID: 21881888)
1. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
[TBL] [Abstract][Full Text] [Related]
2. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
[TBL] [Abstract][Full Text] [Related]
3. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
4. Eprosartan: a review of its use in hypertension.
Plosker GL
Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
[TBL] [Abstract][Full Text] [Related]
5. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
6. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
7. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
[TBL] [Abstract][Full Text] [Related]
8. Eprosartan: a review of its use in the management of hypertension.
Plosker GL; Foster RH
Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
[TBL] [Abstract][Full Text] [Related]
9. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan.
McClellan KJ; Balfour JA
Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
[TBL] [Abstract][Full Text] [Related]
11. Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.
Petrella RJ; Tremblay G; De Backer G; Gill DP;
Vasc Health Risk Manag; 2014; 10():63-74. PubMed ID: 24493928
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
13. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
[TBL] [Abstract][Full Text] [Related]
14. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
[TBL] [Abstract][Full Text] [Related]
16. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
17. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
Maier H; Hehemann K; Vieth M
Cesk Patol; 2015; 51(2):87-8. PubMed ID: 25970720
[TBL] [Abstract][Full Text] [Related]
18. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
20. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA; Punzi CF
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
